Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Colorcon
Mallinckrodt
Federal Trade Commission
Baxter
Daiichi Sankyo
Johnson and Johnson
US Army
Farmers Insurance
Julphar

Generated: August 21, 2017

DrugPatentWatch Database Preview

Glaxosmithkline Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXOSMITHKLINE, and when can generic versions of GLAXOSMITHKLINE drugs launch?

GLAXOSMITHKLINE has one hundred and fifty-eight approved drugs.

There are fifty-seven US patents protecting GLAXOSMITHKLINE drugs.

There are one thousand one hundred and seventeen patent family members on GLAXOSMITHKLINE drugs in sixty-nine countries.

Summary for Applicant: Glaxosmithkline

Patents:57
Tradenames:113
Ingredients:95
NDAs:158
Drug Master File Entries: (click here to view)8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
TOTACILLIN
ampicillin/ampicillin trihydrate
FOR SUSPENSION;ORAL062223-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-001Jun 23, 1995ABRXYesNo► Subscribe► Subscribe ► Subscribe
Glaxosmithkline
ANORO ELLIPTA
umeclidinium bromide; vilanterol trifenatate
POWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Glaxosmithkline
ANORO ELLIPTA
umeclidinium bromide; vilanterol trifenatate
POWDER;INHALATION203975-001Dec 18, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Glaxosmithkline
TAGAMET
cimetidine
TABLET;ORAL017920-005Apr 30, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Glaxosmithkline

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-001Sep 19, 1997► Subscribe► Subscribe
Glaxosmithkline
ZYBAN
bupropion hydrochloride
TABLET, EXTENDED RELEASE;ORAL020711-003May 14, 1997► Subscribe► Subscribe
Glaxosmithkline
WELLBUTRIN SR
bupropion hydrochloride
TABLET, EXTENDED RELEASE;ORAL020358-001Oct 4, 1996► Subscribe► Subscribe
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-002Aug 26, 1997► Subscribe► Subscribe
Glaxosmithkline
VENTOLIN HFA
albuterol sulfate
AEROSOL, METERED;INHALATION020983-001Apr 19, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GLAXOSMITHKLINE drugs

Drugname Dosage Strength Tradename Submissiondate
lamotrigine
Extended-release Tablets25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg
LAMICTAL XR
2/12/2014
nicotine polacrilex
Gum2 mg
NICORETTE
1/22/2013
nicotine polacrilex
Gum4 mg
NICORETTE
1/22/2013
dutasteride and tamsulosin hydrochloride
Capsule0.5 mg/0.4 mg
JALYN
10/26/2010
atovaquone and proguanil hydrochloride
Tablets62.5 mg/25 mg
MALARONE
9/14/2010
orlistat
Capsules60 mg
ALLI
9/8/2010
lamotrigine
Orally Disintegrating Tablets25 mg, 50 mg, 100 mg, and 200 mg
LAMICTAL ODT
12/21/2009
atovaquone
Oral Suspension750 mg/5 mL
MEPRON
10/20/2009
ropinirole hydrochloride
Extended-release Tablets6 mg
REQUIP XL
7/22/2009
atovaquone and proguanil hydrochloride
Tablets250 mg/100 mg
MALARONE
4/3/2009
ropinirole hydrochloride
Extended-release Tablets12 mg
REQUIP XL
2/5/2009
ropinirole hydrochloride*
Extended-release Tablets3 mg
REQUIP XL
1/8/2009
ropinirole hydrochloride
Extended-release Tablets3 mg
REQUIP XL
1/8/2009
ropinirole hydrochloride
Extended-release Tablets8 mg
REQUIP XL
11/3/2008
ropinirole hydrochloride
Extended-release Tablets4 mg
REQUIP XL
10/31/2008
ropinirole hydrochloride
Extended-release Tablets2 mg
REQUIP XL
10/14/2008
lamivudine
Tablets100 mg
EPIVIR-HBV
10/31/2007
ranitidine hydrochloride
Tablets150 mg
ZANTAC 150
10/30/2007
dutasteride
Capsules0.5 mg
AVODART
10/29/2007
propafenone
Extended-release Capsules325 mg
RYTHMOL SR
11/7/2006
propafenone hydrochloride
Extended-release Capsules225 mg and 425 mg
RYTHMOL SR
10/11/2006
sumatriptan succinate
Injection6 mg/0.5 mL, 0.5 mL (prefilled syringes)
IMITREX
5/9/2006
ropinirole hydrochloride
Tablets3 mg, 4 mg and 5 mg
REQUIP
2/4/2005
ropinirole hydrochloride
Tablets0.25 mg, 0.5 mg, 1 mg and 2 mg
REQUIP
12/22/2004
sumatriptan succinate
Injection6 mg/0.5 mL, 0.5 mL vials
IMITREX
10/25/2004

Non-Orange Book Patents for Glaxosmithkline

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,656,453 Medicaments► Subscribe
9,636,471Medicament dispenser► Subscribe
6,777,399 Anti-inflammatory androstane derivative compositions► Subscribe
6,792,945 Inhalation device► Subscribe
7,225,808Inhalation device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Glaxosmithkline Drugs

Country Document Number Estimated Expiration
Hungary0300530► Subscribe
Israel97396► Subscribe
Japan4436041► Subscribe
Yugoslavia47799► Subscribe
Denmark0969815► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Glaxosmithkline Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
00694Netherlands► SubscribePRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
C0136Belgium► SubscribePRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Accenture
Chinese Patent Office
Healthtrust
Cipla
Farmers Insurance
Colorcon
Baxter
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot